Attovia Therapeutics, Inc.

Attovia Therapeutics IPO: A Phase 1 Anti-IL-31 Story Priced Before the Phase 2 Data

In-depth research on ATTO covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.